Calidi Biotherapeutics Receives NYSE American Listing Deficiency Notice

SAN DIEGO, Sept. 25, 2026 /CourierPR/ -- Calidi Biotherapeutics, a biotechnology company developing targeted genetic medicines, has received a notification from the NYSE American regarding its stockholders' equity. On September 21, 2026, the company was informed that it was not in compliance with the NYSE American's continued listing standards. Specifically, the company failed to meet the requirement of having stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.

The NYSE American's listing standards require companies to maintain a minimum stockholders' equity of $4.0 million if they have reported losses from continuing operations and/or net losses in three of their four most recent fiscal years. Calidi Biotherapeutics is not currently eligible for any exemptions, including those for companies with a market capitalization exceeding $50 million.

To regain compliance, Calidi Biotherapeutics must submit a plan to the NYSE American by October 21, 2026. The plan should outline actions the company will take to meet the listing standards by March 21, 2028. If the NYSE American accepts the plan, the company will be subject to periodic reviews, including quarterly monitoring for compliance. If the company fails to submit a plan or if the plan is not accepted, NYSE American will commence delisting proceedings. Additionally, if the company does not regain compliance by March 21, 2028, or if it does not make progress consistent with its plan, delisting proceedings will be initiated.

Calidi Biotherapeutics is currently headquartered in San Diego, California. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. CLD-401, the lead candidate from the RedTail platform, is currently in IND-enabling studies and targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. The company continues to advance its pipeline utilizing the RedTail platform, including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi Biotherapeutics has stated that it is reviewing its options to address the deficiencies and expects to submit a compliance plan on or before the deadline set by the NYSE American. The company's annual report, filed on March 27, 2026, provides further details on its financial and operational status.